{"filing":{"accession_number":"0001724521-26-000042","cik":"0001724521","ticker":"RCUS","company_name":"Arcus Biosciences, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"rcus-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452126000042/rcus-20260805.htm"},"events":[{"id":25224,"run_id":22889,"accession_number":"0001724521-26-000042","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Arcus Biosciences issued a press release on August 5, 2026 announcing financial results for the six months ended June 30, 2026, disclosing Q2 2026 revenues ($41 million), R\u0026D expenses ($113 million), G\u0026A expenses ($24 million), net loss ($91 million), and cash position ($775 million). The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the full press release furnished as Exhibit 99.1, which is the standard format for earnings releases.","company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25992,"accession_number":"0001724521-26-000042","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Arcus Biosciences issued a press release on August 5, 2026 announcing financial results for the six months ended June 30, 2026, disclosing Q2 2026 revenues ($41 million), R\u0026D expenses ($113 million), G\u0026A expenses ($24 million), net loss ($91 million), and cash position ($775 million). The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the full press release furnished as Exhibit 99.1, which is the standard format for earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:20:35.118420+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25992,"accession_number":"0001724521-26-000042","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Arcus Biosciences issued a press release on August 5, 2026 announcing financial results for the six months ended June 30, 2026, disclosing Q2 2026 revenues ($41 million), R\u0026D expenses ($113 million), G\u0026A expenses ($24 million), net loss ($91 million), and cash position ($775 million). The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the full press release furnished as Exhibit 99.1, which is the standard format for earnings releases.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:20:35.118420+00:00","company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","filing_date":"2026-08-05"}]}